| 000 | 00911 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250514161031.0 | ||
| 264 | 0 | _c20031223 | |
| 008 | 200312s 0 0 eng d | ||
| 022 | _a1088-0224 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNagle, Paul C | |
| 245 | 0 | 0 |
_aDefining and characterizing the late-stage biopharmaceutical pipeline. _h[electronic resource] |
| 260 |
_bThe American journal of managed care _cOct 2003 |
||
| 300 |
_aS124-35 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aBiopharmaceutics _xclassification |
| 650 | 0 | 4 | _aDrugs, Investigational |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 700 | 1 | _aLugo, Timothy F | |
| 700 | 1 | _aNicita, Christopher A | |
| 773 | 0 |
_tThe American journal of managed care _gvol. 9 _gno. 6 Suppl _gp. S124-35 |
|
| 999 |
_c14319578 _d14319578 |
||